CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interest	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Shareholders' Equity Attributable to Bruker Corporation	Noncontrolling Interests in Consolidated Subsidiaries
Balance at beginning of period at Dec. 31, 2018	$ 905.1	$ 22.6	$ 1.7	$ (401.5)	$ 176.9	$ 1,102.5	$ 17.0	$ 896.6	$ 8.5
Balance (in shares) at Dec. 31, 2018			156,609,340	16,024,880
Increase (Decrease) in Stockholders' Equity
Stock options exercised	12.0				12.0			12.0
Stock options exercised (in shares)			626,796
RSU vested	(1.1)				(1.1)			(1.1)
RSU vested (in shares)			241,359
Stock based compensation	11.9				11.9			11.9
Cash dividends paid to common stockholders	(25.0)					(25.0)		(25.0)
Consolidated net income	199.1	(1.1)				197.2		197.2	1.9
Shares repurchased	(142.3)			$ (142.3)				(142.3)
Shares repurchased (in shares)			(3,323,104)	3,323,104
Treasury stock acquired	(0.1)			$ (0.1)				(0.1)
Treasury stock acquired (in shares)			(1,680)	1,680
Shares issued for acquisition	0.1			$ 0.1				0.1
Shares issued for acquisition (in shares)			3,087	(3,087)
Other comprehensive income (loss)	(42.6)	(0.4)					(42.5)	(42.5)	(0.1)
Balance at end of period at Dec. 31, 2019	917.1	21.1	$ 1.7	$ (543.8)	199.7	1,274.7	(25.5)	906.8	10.3
Balance (in shares) at Dec. 31, 2019			154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	4.9				4.9			4.9
Stock options exercised (in shares)			241,915
RSU vested	(1.6)				(1.6)			(1.6)
RSU vested (in shares)			301,320
Distributions to noncontrolling interests	(1.2)								(1.2)
Stock based compensation	13.3				13.3			13.3
Cash dividends paid to common stockholders	(24.7)					(24.7)		(24.7)
Acquired remaining 20% interest in Hain LifeScience GmbH	(1.3)	(20.6)				(1.3)		(1.3)
Consolidated net income	161.4					157.8		157.8	3.6
Shares repurchased	(123.2)			$ (123.2)				(123.2)
Shares repurchased (in shares)			(2,711,952)	2,711,952
Other comprehensive income (loss)	29.6	(0.5)					29.2	29.2	0.4
Balance at end of period at Dec. 31, 2020	974.3	0.0	$ 1.7	$ (667.0)	216.3	1,406.5	3.7	961.2	13.1
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	11.7				11.7			11.7
Stock options exercised (in shares)			580,656
RSU vested	(4.7)				(4.7)			(4.7)
RSU vested (in shares)			278,769
Stock based compensation	14.5				14.5			14.5
Cash dividends paid to common stockholders	(24.1)					(24.1)		(24.1)
Formation of Acuity Spatial Genomics Inc.		0.3
Consolidated net income	280.7	(0.1)				277.1		277.1	3.6
Shares repurchased	(153.3)			$ (153.3)				(153.3)
Shares repurchased (in shares)			(2,092,819)	2,092,819
Other comprehensive income (loss)	(14.5)	0.0					(11.9)	(11.9)	(2.6)
Balance at end of period at Dec. 31, 2021	$ 1,084.6	$ 0.2	$ 1.7	$ (820.3)	$ 237.8	$ 1,659.5	$ (8.2)	$ 1,070.5	$ 14.1
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348